Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Life-Sciences Industry Would Pay £10M In Fees Each Year To UK NICE Under Proposal

Executive Summary

England’s department of health is again consulting on plans to allow the health technology appraisal body NICE to charge companies for conducting appraisals.

You may also be interested in...



Moonshot Projects In Life Sciences Strategy Can Lift UK Over Brexit Hurdle

The long-awaited UK Life Sciences Strategy, part of the industrial strategy proposed after the May government took office in summer 2016, was released today. With input from major medtech organizations and UK-based pharma groups it charts a course ahead for the £64bn national life-sciences industry as the UK seeks to embrace its post-EU future.

NICE Cost Recovery Plans Pause Is Welcome News For UK Industry

UK health technology body NICE will wait for the government to finalize its life sciences strategy before deciding on whether to go ahead with its plan to levy a fee for technology appraisals. Pharmaceutical and medtech companies say the delay will allow more time for their concerns over the proposal to be explored.

As Appraisal Fees Loom, NICE Says No To Industry Calls For Reform

A proposal by the UK's HTA body NICE to charge companies for technology appraisals has raised several issues, such as the need for reforms to the HTA process, ensuring independence and credibility of appraisals, greater accountability and transparency at NICE, and the impact of fees on bringing new medicines to market.

Topics

UsernamePublicRestriction

Register

MT123180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel